Rate of infection with tofacitinib higher than TNF inhibitors among patients with RA
Rates of infection with tofacitinib in rheumatoid arthritis are higher than with tumour necrosis factor (TNF) inhibitors according to a recent study published in the Annals of the Rheumatic Diseases.
A study was conducted to characterise infections in patients with rheumatoid arthritis (RA) in ORAL Surveillance.
In this open-label, randomised controlled trial, patients with RA aged≥50 years with ≥1 additional cardiovascular risk factor received tofacitinib 5 or 10 mg two times per day or a tumour necrosis factor inhibitor (TNFi). Incidence rates (IRs; patients with first events/100 patient-years) and hazard ratios (HRs) were calculated for infections, overall and by age (50–<65 years; ≥65 years). Probabilities of infections were obtained (Kaplan-Meier estimates). Cox modelling identified infection risk factors.
Results
- IRs/HRs for all infections, serious infection events (SIEs) and non-serious infections (NSIs) were higher with tofacitinib (10>5 mg two times per day) versus TNFi.
- For SIEs, HR (95% CI) for tofacitinib 5 and 10 mg two times per day versus TNFi, respectively, were 1.17 (0.92 to 1.50) and 1.48 (1.17 to 1.87).
- Increased IRs/HRs for all infections and SIEs with tofacitinib 10 mg two times per day versus TNFi were more pronounced in patients aged≥65 vs 50–<65 years.
- SIE probability increased from month 18 and before month 6 with tofacitinib 5 and 10 mg two times per day versus TNFi, respectively.
- NSI probability increased before month 6 with both tofacitinib doses versus TNFi.
- Across treatments, the most predictive risk factors for SIEs were increasing age, baseline opioid use, history of chronic lung disease and time-dependent oral corticosteroid use, and, for NSIs, female sex, history of chronic lung disease/infections, past smoking and time-dependent Disease Activity Score in 28 joints, C-reactive protein.
Infections were higher with tofacitinib versus TNFi. Findings may inform future treatment decisions.
Reference:
Balanescu A-R, et al "Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial" Ann Rheum Dis 2022; DOI: 10.1136/ard-2022-222405.
